Browsing: Selpercatinib
Researchers identify cryptic vulnerabilities in an oncoprotein
RET is a receptor protein with tyrosine kinase activity that can transfer a phosphate group…
AACR 2021: FDA-approved selpercatinib shows clinical benefits for RET fusion-positive cancers beyond lung and thyroid cancers
Clinical trial results of RET kinase inhibitor selpercatinib show that the targeted therapy was effective…
The Oncology Journal Club Episode 16
We’re back to our standard format for today’s episode of The Oncology Journal Club This…
Clinical trial of selpercatinib shows strong response for patients with non-small cell lung cancer
An international team of researchers has found that selpercatinib, a drug that precisely targets cancers…
Strong, durable responses to selpercatinib in RET-driven medullary thyroid cancer
Selpercatinib (Retevmo), a drug targeted precisely against cancers driven by mutations or alterations in the…
Lung cancer trial of RET inhibitor selpercatinib achieves durable responses in majority of patients with RET gene fusions
For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted…
FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions
The Food and Drug Administration (FDA) granted accelerated approval to selpercatinib for the following indications:…
Updated results on genomically tailored therapy for lung cancer patients
Selpercatinib was granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration in 2018…